Skip to main content

New study casts doubt on hyrdoxychloroquine’s effectiveness in treating coronavirus

In a prime example of why President Trump shouldn’t be endorsing any unproven potential treatments for the novel coronavirus behind the current global pandemic, a new small-scale study by researchers in China indicates that the antimalarial drug hydroxychloroquine actually isn’t any more effective than standard, existing best practice for conventional care of patients with the virus.

The study, which included 30 patients with a control of 15 who received no treatment, with the other half being treated with hydroxychloroquine, showed that there was a statistically insignificant difference in the number of patients who tested negative for the drug after a week. During the study, those who received conventional treatment were provided anti-virals that are currently recommended for use in China, including Iopinavir and ritonavir, and after a week, 13 of the 15 control patients showed no sign of the virus, while 14 of the 15 who were treated with hydroxychloroquine showed the same.

An earlier small-scale study of 30 patients by French researchers published last week had shown indication that hydroxychloroquine used alone was effective in reducing the duration and severity of COVID-19, while using it in combination with an antibiotic called azithromycin increased its effectiveness. The study has been criticized by some for its methods – which is the entire purpose of scientific study and medical research, wherein people submit their studies for peer review prior to publication, and then other researchers challenge their assumptions, results and findings.

Trump is obviously not a scientist or medical professional, and yet he has been touting the efficacy of hydroxychloroquine and chloroquine during the White House’s daily coronavirus task force press briefings, and on Twitter, including when he called for them to be “put in use IMMEDIATELY” on March 21. The drug can be lethal in doses that exceed physician’s guidance, however, and a Phoenix-area couple subsequently self-medicated with a form of chloroquine used for cleaning aquariums, citing the President’s information about it as the cause of their decision to take it.

White House task force member Dr. Anthony Fauci has attempted to dissuade anyone from reading too much into what amount to scattered and early scientific research results, but Fauci seems to be falling out of favor with Trump and has not appeared on recent task force briefings.

The bottom line is that all of these potential treatments require, as Fauci has said, proper large-scale clinical trials before any definitive statements can be made about their efficacy against the coronavirus one way or the other. Relying on small scale investigations means that you will see variances in results, which is why you do large-scale testing with proper controls to arrive at more consistent and verifiable research.

Medical professionals around the world are working tirelessly to research various forms of treatment, and to launch exactly these kinds of clinical trials, but they will take time to produce results – and then corroborating research will need to be conducted to show that their results are repeatable and reliable. Meanwhile, treatment using unproven methods will continue due to the severe and life-threatening nature of this disease, which has encouraged the FDA to allow case-by-case use of methods without formal approval on compassionate and investigatory grounds. That said, no one (least of all the President), should be pointing to these as proven solutions before public health agencies have actually done the work to certify them as such.



from TechCrunch https://ift.tt/3bqQyPu
via IFTTT

Comments

Popular posts from this blog

The Silent Revolution of On-Device AI: Why the Cloud Is No Longer King

Introduction For years, artificial intelligence has meant one thing: the cloud. Whether you’re asking ChatGPT a question, editing a photo with AI tools, or getting recommendations on Netflix — those decisions happen on distant servers, not your device. But that’s changing. Thanks to major advances in silicon, model compression, and memory architecture, AI is quietly migrating from giant data centres to the palm of your hand. Your phone, your laptop, your smartwatch — all are becoming AI engines in their own right. It’s a shift that redefines not just how AI works, but who controls it, how private it is, and what it can do for you. This article explores the rise of on-device AI — how it works, why it matters, and why the cloud’s days as the centre of the AI universe might be numbered. What Is On-Device AI? On-device AI refers to machine learning models that run locally on your smartphone, tablet, laptop, or edge device — without needing constant access to the cloud. In practi...

Apple’s AI Push: Everything We Know About Apple Intelligence So Far

Apple’s WWDC 2025 confirmed what many suspected: Apple is finally making a serious leap into artificial intelligence. Dubbed “Apple Intelligence,” the suite of AI-powered tools, enhancements, and integrations marks the company’s biggest software evolution in a decade. But unlike competitors racing to plug AI into everything, Apple is taking a slower, more deliberate approach — one rooted in privacy, on-device processing, and ecosystem synergy. If you’re wondering what Apple Intelligence actually is, how it works, and what it means for your iPhone, iPad, or Mac, you’re in the right place. This article breaks it all down.   What Is Apple Intelligence? Let’s get the terminology clear first. Apple Intelligence isn’t a product — it’s a platform. It’s not just a chatbot. It’s a system-wide integration of generative AI, machine learning, and personal context awareness, embedded across Apple’s OS platforms. Think of it as a foundational AI layer stitched into iOS 18, iPadOS 18, and m...

Max Q: Anomalous

Hello and welcome back to Max Q! Last week wasn’t the most successful for spaceflight missions. We’ll get into that a bit more below. In this issue: First up, a botched launch from Virgin Orbit… …followed by one from ABL Space Systems News from Rocket Lab, World View and more Virgin Orbit’s botched launch highlights shaky financial future After Virgin Orbit’s launch failure last Monday, during which the mission experienced an  “anomaly” that prevented the rocket from reaching orbit, I went back over the company’s financials — and things aren’t looking good. For Virgin Orbit, this year has likely been completely turned on its head. The company was aiming for three launches this year, but everything will remain grounded until the cause of the anomaly has been identified and resolved. It’s unclear how long that will take, but likely at least three months. Add this delay to Virgin’s dwindling cash reserves and you have a foundation that’s suddenly much shakier than before. ...